BACE1 and Alzheimer disease: EMPA was found to improve memory and learning capabilities and also affect signaling pathways such as upregulation of p-AMPK, p-mTOR, and HO-1, reducing AD hallmarks (β-amyloid and BACE1), neuro-inflammation, and oxidative stress sequelae.